Iradimed Corp

Name: Iradimed Corp standardized financial statements, quarterly
Creator: Listed

IRMDNasdaqCIK 1325618HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$20.5m, Q2 FY2026

Operating income$6.4m, Q2 FY2026

Net income$5.2m, Q2 FY2026

Iradimed Corp, income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	16.5	17.5	17.6	17.9	18.3	19.4	19.5	20.4	21.2	22.7	22.0	20.5
Cost of revenue	$m	3.7	4.0	4.2	3.9	4.1	4.6	4.7	4.5	4.7	5.7	5.2	5.3
Gross profit	$m	12.8	13.4	13.4	14.0	14.2	14.8	14.8	16.0	16.5	17.0	16.8	15.2
Research and development	$m	0.5	0.7	0.8	0.8	0.6	0.6	0.6	0.9	0.7	0.8	1.0	0.7
Operating income	$m	5.9	5.2	4.7	5.6	5.8	5.8	5.4	6.8	6.8	7.1	7.2	6.4
Income tax	$m	1.3	1.1	1.1	1.4	1.4	1.2	1.3	1.6	1.7	1.3	2.0	1.7
Net income	$m	5.1	4.5	4.1	4.9	5.0	5.1	4.7	5.8	5.6	6.4	5.8	5.2
Diluted EPS	$ per share	0.40	not reported	0.32	0.38	0.40	not reported	0.37	0.45	0.43	not reported	0.45	0.41
Basic EPS	$ per share	0.40	not reported	0.33	0.39	0.40	not reported	0.37	0.45	0.44	not reported	0.46	0.41

Balance sheet

Cash and equivalents$59.1m, Q2 FY2026

Shareholders' equity$101.7m, Q2 FY2026

Iradimed Corp, balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	46.7	49.8	45.1	48.5	51.7	52.2	50.3	53.0	56.5	51.2	56.4	59.1
Current assets	$m	71.9	76.0	71.9	73.6	74.3	75.2	75.1	77.4	84.9	81.2	86.4	86.7
Total assets	$m	87.4	92.2	88.0	89.9	94.2	98.3	102	106	115	109	114	115
Current liabilities	$m	7.9	16.3	7.6	7.5	8.1	8.5	8.5	8.8	12.8	10.2	12.1	9.2
Total liabilities	$m	12.8	20.7	11.9	10.3	10.8	11.5	11.7	12.1	16.4	14.2	15.9	13.2
Shareholders' equity	$m	74.6	71.4	76.1	79.7	83.4	86.8	90.1	94.3	98.4	94.6	98.5	102

Cash flow

Operating cash flow$5.9m, Q2 FY2026

Capital expenditure$185.0k, Q2 FY2026

Iradimed Corp, cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	1,393	3,912	3,883	6,639	9,116	5,987	4,292	7,747	6,985	5,923	8,290	5,940
Capital expenditure	$k	308	532	271	1,134	3,810	2,790	3,697	2,636	1,138	294	403	185
Dividends paid	$k	0.0	0.0	7,976	1,900	1,900	1,901	2,162	2,161	2,163	8,554	2,556	2,557
Share repurchases	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)12.87m, Q2 FY2026

Iradimed Corp, shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	12.6	12.7	12.7	12.7	12.7	12.8	12.8	12.8	12.8	12.9	12.9	12.9

Shares outstanding: 12.79m at Jul 31, 2026, from the cover of the 10-Q filed Jul 31, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. Listed shows no prices and gives no investment advice.